Metformin use and risk of prostate cancer: results from the REDUCE study.

about

Potential role for metformin in urologic oncology Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

P2860

Q26747759-3B9F414C-8FD0-44B7-A945-749904823CE6 Q37561605-269217A1-59D5-4945-9435-052C78E38E74 Q39124486-A2EF1287-B2E5-47C6-9103-7E8BAE4D718F

P2860

Metformin use and risk of prostate cancer: results from the REDUCE study.

Item

http://www.wikidata.org/entity/Q36296255

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Metformin use and risk of prostate cancer: results from the REDUCE study.

@ast

Metformin use and risk of prostate cancer: results from the REDUCE study.

@en

type

Item

label

Metformin use and risk of prostate cancer: results from the REDUCE study.

@ast

Metformin use and risk of prostate cancer: results from the REDUCE study.

@en

prefLabel

Metformin use and risk of prostate cancer: results from the REDUCE study.

@ast

Metformin use and risk of prostate cancer: results from the REDUCE study.

@en

P1476

Metformin use and risk of prostate cancer: results from the REDUCE study.

@en

P2093

Adriana C Vidal

http://www.w3.org/2001/XMLSchema#string

Alexis R Gaines

http://www.w3.org/2001/XMLSchema#string

Gerald L Andriole

http://www.w3.org/2001/XMLSchema#string

Lauren E Howard

http://www.w3.org/2001/XMLSchema#string

Ramiro Castro-Santamaria

http://www.w3.org/2001/XMLSchema#string

Stephen J Freedland

http://www.w3.org/2001/XMLSchema#string

Tom Feng

http://www.w3.org/2001/XMLSchema#string

Xizi Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Cancer statistics, 2014

Metformin and reduced risk of cancer in diabetic patients

Effect of dutasteride on the risk of prostate cancer.

Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

P304

1055-1060

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-15-0141

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel M. Moreira

P577

2015-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26353947

http://www.w3.org/2001/XMLSchema#string

P921

metformin

P932

4651624

http://www.w3.org/2001/XMLSchema#string

Metformin use and risk of prostate cancer: results from the REDUCE study.

about

P2860

P2860

Metformin use and risk of prostate cancer: results from the REDUCE study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932